cas 2590559-38-7|| where to buy 3-(6-Chloro-4-pyrimidinyl)-7-fluoroimidazo[1,2-a]pyridine

Название продукции:3-(6-Chloro-4-pyrimidinyl)-7-fluoroimidazo[1,2-a]pyridine

IUPAC Name:4-chloro-6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}pyrimidine

: CAS：2590559-38-7; Молекулярная формула：C11H6ClFN4; Чистота：95%

Упаковочная единица	Доступно для заказа	Цена ($)	Количество

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2590559-38-7 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:2590559-38-7; Молекулярная формула:C11H6ClFN4; Точка плавления:-; Smiles-код:FC=1C=CN2C(=NC=C2C=3N=CN=C(Cl)C3)C1; Плотность:

: Номер в каталоге:CM1078450; Молекулярная масса:248.65; Точка кипения:; Номер Mdl:; Хранение:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: IDRX-42; IDRx announces $120 million series B financing to advance potential best-in-class new treatment for gastrointestinal stromal tumor (GIST). IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant GIST (including variants in exons 9, 11, 13 and 17). IDRX-42 was granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 is currently being evaluated in StrateGIST 1, a first-in-human Phase 1/1b study.
In preclinical studies, IDRX-42 demonstrated superior antitumor activity compared to imatinib, the current first-line of therapy, in GIST human xenograft models expressing mutations in KIT exons 9 and 11. In xenograft models expressing secondary resistance mutations in KIT exon 13 or 17, IDRX-42 treatment resulted in potent and dose-dependent antitumor activity superior to the second-line standard of care agent, sunitinib.